A Randomized Placebo-Controlled Trial of Duloxetine for Central Pain in Multiple Sclerosis

Abstract

Fewer patients could tolerate duloxetine compared to placebo. Among patients who completed 6 weeks of treatment, there were significant reductions in average and worst daily pain scores with duloxetine compared to placebo. This study suggests that duloxetine has a direct pain-relieving effect in MS.